Skip to content
10-Q

Quarterly Report

RESPIRERX PHARMACEUTICALS INC.

0001493152-23-018545

← back to feed
Filed
May 22, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 18, 2023 157.03M sh
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$29.19K
Operating Cash Flow Q1 2023 · Dec 31, 2022 −$143.91K
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$23.13K
Cash And Equivalents Q1 2023 · Mar 31, 2023 $138
Cash And Equivalents Q1 2023 · Dec 31, 2022 $88
Stockholders Equity Q1 2023 · Mar 31, 2023 −$12.31M
Stockholders Equity Q1 2023 · Dec 31, 2022 −$11.88M
Stockholders Equity Q1 2023 · Mar 31, 2022 −$10.87M
Stockholders Equity Q1 2023 · Dec 31, 2021 −$10.01M
Current Liabilities Q1 2023 · Mar 31, 2023 $12.29M
Current Liabilities Q1 2023 · Dec 31, 2022 $11.73M
Total Liabilities Q1 2023 · Mar 31, 2023 $12.41M
Total Liabilities Q1 2023 · Dec 31, 2022 $11.9M
Current Assets Q1 2023 · Mar 31, 2023 $95.89K
Current Assets Q1 2023 · Dec 31, 2022 $22.78K
Total Assets Q1 2023 · Mar 31, 2023 $95.89K
Total Assets Q1 2023 · Dec 31, 2022 $22.78K
Eps Basic Q1 2023 · Mar 31, 2023 −$0.01
Eps Basic Q1 2023 · Mar 31, 2022 −$0.01
Sga Expense Q1 2023 · Mar 31, 2023 $291.95K
Sga Expense Q1 2023 · Mar 31, 2022 $495.79K
Rd Expense Q1 2023 · Mar 31, 2023 $98.43K
Rd Expense Q1 2023 · Mar 31, 2022 $121.16K
Net Income Q1 2023 · Mar 31, 2023 −$430.06K
Net Income Q1 2023 · Dec 31, 2022 −$2.1M
Net Income Q1 2023 · Mar 31, 2022 −$860.16K
Operating Income Q1 2023 · Mar 31, 2023 −$390.37K
Operating Income Q1 2023 · Mar 31, 2022 −$616.95K